ICON Clinical Research Limited Sustainability Profile
ICON Clinical Research Limited, headquartered in Ireland (IE), is a leading global provider of outsourced development and commercialisation services to the pharmaceutical, biotechnology, and medical device industries. Founded in 1990, ICON has established itself as a trusted partner in clinical research, with a strong presence across Europe, North America, and Asia-Pacific. The company offers a comprehensive range of services, including clinical trial management, data management, and regulatory affairs, distinguished by its commitment to innovation and quality. ICON's unique approach integrates advanced technology and deep therapeutic expertise, enabling clients to navigate the complexities of clinical development efficiently. Recognised for its market leadership, ICON has achieved numerous accolades, reflecting its dedication to excellence and client satisfaction. With a robust portfolio and a focus on delivering results, ICON Clinical Research Limited continues to shape the future of clinical trials globally.
DitchCarbon Score
How does ICON Clinical Research Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
ICON Clinical Research Limited's score of 92 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
ICON Clinical Research Limited, headquartered in Ireland (IE), currently does not report specific carbon emissions data for the most recent year. As a current subsidiary of ICON Public Limited Company, any emissions data or climate commitments would be inherited from this parent organization. ICON Public Limited Company has established various climate initiatives, including commitments to the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP). However, specific reduction targets or achievements for ICON Clinical Research Limited are not detailed in the available information. As part of its corporate family, ICON Clinical Research Limited aligns with broader industry standards and practices aimed at reducing carbon footprints and enhancing sustainability. The absence of specific emissions data highlights the need for ongoing transparency and commitment to climate action within the organisation.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 1,827,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 18,812,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 36,726,000 | 0,000,000 | 0,000,000 | 0,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is ICON Clinical Research Limited's Industry?
How Carbon Intensive is ICON Clinical Research Limited's Location?
ICON Clinical Research Limited's Scope 3 Categories Breakdown
ICON Clinical Research Limited's Scope 3 emissions, which decreased by 0% last year and increased by approximately 872% since 2018, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 54% of Scope 3 emissions.
Top Scope 3 Categories
ICON Clinical Research Limited's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
ICON Clinical Research Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
